Imagine you’re at the doctor’s office facing one of the scariest diagnoses out there: cancer. In that moment, nothing is more important than knowing there is hope for treatment and recovery. With so much time and money spent looking for a way to fight this disease, companies must set themselves apart not just with their products but with a high level of commitment and care to truly making a difference. Galena Biopharma is one of these companies.
Galena Biopharma is a developer of innovative, targeted oncology treatments. The treatments address major unmet medical needs designed to advance cancer care. Though the company has several projects targeted at various forms of cancer, Galena’s primary focus is on treating breast cancer. More specifically, the company is looking to prevent breast cancer from recurring in patients who have been diagnosed and treated previously.
Breast cancer is becoming increasingly more common in the United States. With over 230,000 women diagnosed every year, about 25% of node-positive patients relapse within three years of being treated. For these women, Gelena has developed NeuVax™, a novel cancer immunotherapy. NeuVax™ is an innovative and helpful therapy, but its major selling point is that it’s the only one of its kind. As the proprietor of the only late-stage breast cancer vaccine currently in development, Gelena has the market cornered on this type of therapy, making it an exciting time for patients and shareholders alike.
NeuVax™ has been in the company’s pipeline for a while, but reached an important milestone in the first quarter of 2012: phase 3 clinical trials. The pivotal trials are currently enrolling in over 100 sites around North America, Europe, and Israel; if the trials show positive results, NeuVax™ will be on the fast track to gaining FDA approval. The vaccine will be a huge breakthrough in cancer treatments, and will help Galena and breast cancer survivors realize their vision of living free from fear of the cancer metastasizing.
Though Galena could focus only on NeuVax™ and still make waves in cancer therapy, the company has a whole host of over innovative products to support its reputation as an aggressive, go-getting force to be reckoned with. In March 2013, Galena acquired Abstral® Sublingual Tablets, a product that is believed to significantly improve care for cancer patients who experience breakthrough pain during treatment. The innovative, FDA-approved Abstra® l formulation rapidly dissolves under the tongue with predictable dosing, is easy to use and convenient to carry, but most importantly, provides rapid relief of patients’ breakthrough pain.
Galena, always a forward-thinking company, acquired Abstral® to produce near-term revenues while they wait for NeuVax™’s launch. The company expects the revenue from Abstral® to reduce its overall cash burn in that waiting period, but the product also provides an avenue for the company to build relationships with future NeuVax™ prescribers. Galena reps say that these clients include oncologists, who could be treating patients with advanced breast cancer or patients experiencing breakthrough pain.
The company’s current financial status serves as an appropriate compliment to its product suite. The company is well positioned thanks to Galena’s strong leadership team of individuals with experience in developing and commercializing cancer treatment drug candidates. What’s more, the company has recently expanded its Scientific Advisory Board with distinguished leaders in the field of oncology whose expertise is crucial to advancing the product pipeline.
All of these factors contribute to Galena’s presence as not only an innovative solutions provider, but as a company truly dedicated to improving the lives of the people whom it’s trying to help. Bolstered by its ever-expanding pipeline and multiple development and commercial partnerships, Galena’s suite of immunotherapeutic solutions is bound to take the industry by storm.
For more information, visit www.galenabiopharma.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html
